Current Clinical Pathology

Total Page:16

File Type:pdf, Size:1020Kb

Current Clinical Pathology Current Clinical Pathology Antonio Giordano, Md, Phd SERIES EDITOR For further volumes: http://www.springer.com/series/7632 Antonio Russo ● Stefano Iacobelli ● Juan Iovanna Editors Diagnostic, Prognostic and Therapeutic Value of Gene Signatures Editors Antonio Russo, MD, PhD Stefano Iacobelli, MD Section of Medical Oncology National Consortium for Research on Cancer (CINBO) Department of Surgical and Oncological Sciences University D’Annunzio University of Palermo Chieti 66013, Italy Palermo, Italy [email protected] [email protected] Juan Iovanna, MD, PhD INSERM U624 Marseille 13288, France [email protected] ISBN 978-1-61779-357-8 e-ISBN 978-1-61779-358-5 DOI 10.1007/978-1-61779-358-5 Springer New York Dordrecht Heidelberg London Library of Congress Control Number: 2011937026 © Springer Science+Business Media, LLC 2012 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Humana Press, c/o Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein. Printed on acid-free paper Humana Press is part of Springer Science+Business Media (www.springer.com) Preface Gene expression studies have revealed diagnostic profiles and upregulation of specific pathways in many solid tumors. Some gene-expression signatures are already used as predictors of relapse in early breast cancer patients. The explosion of new information in gene expression profiling could potentially lead to the development of tailored treatments in many solid tumors. In addition, many studies are ongoing to validate these signatures also in predicting response to hormonal, chemo- therapeutic, and targeted agents in breast cancer as well as in other tumors. This book has been carried out with the aim of providing readers a useful and comprehensive resource about the range of applications of microarray technology on oncological diseases. The book is principally addressed to resident and fellow physicians, medical oncologists, molec- ular biologists, biotechnologists, and those who study oncological diseases. The chapters have been written by leading international researchers on these topics who have prepared their manuscripts according to current literature and field experience with microarray technology. Palermo, Italy Antonio Russo Chieti, Italy Stefano Iacobelli Marseille, France Juan Iovanna v Contents 1 Gene Signatures and Soft Tissue Sarcomas: Status of Art and Perspectives ..................................................................................................... 1 Bruno Vincenzi, Anna Maria Frezza, Daniele Santini, and Giuseppe Tonini 2 Heterogeneity of Breast Cancer: Gene Signatures and Beyond ................................... 13 Gaia Schiavon, Marcel Smid, Gaorav P. Gupta, Stefania Redana, Daniele Santini, and John W.M. Martens 3 Gene Signatures in CRC and Liver Metastasis .............................................................. 27 Daniele Fanale, Lidia Corsini, Sergio Rizzo, and Antonio Russo 4 Gene Signatures in Gastrointestinal Stromal Tumors ................................................... 35 Piotr Rutkowski, Giuseppe Badalamenti, Laura La Paglia, Joanna Przybył, and Maria Debiec-Rychter 5 Pancreatic Cancer Genetics ............................................................................................. 51 Juan Iovanna, Ezequiel Luis Calvo, Jean Charles Dagorn, and Nelson Dusetti 6 Diagnostic, Prognostic, and Therapeutic Value of Gene Signatures in Non-Small Cell Lung Cancer....................................................................................... 81 Rafael Rosell, Miquel Taron, Christian Diego Rolfo, Delvys Rodriguez-Abreu, and Jia Wei 7 Gene Signatures in Gastric Cancer ................................................................................. 95 Laura Ottini, Mario Falchetti, and Gabriella Nesi 8 Gene Signatures in Colorectal Cancer ............................................................................ 115 Alessandro Lugli and Inti Zlobec 9 The Role of Epigenetics in Cancer: From Molecular Function to High-Throughput Assays ............................................................................................. 137 Aleksandra Pekowska, Joaquin Zacarias-Cabeza, Jinsong Jia, Pierre Ferrier, and Salvatore Spicuglia vii viii Contents 10 Primary Epithelial Ovarian Neoplasms: New Concepts Concerning Origin, Pathogenesis and Classifi cation Based on Morphology, Immunomarkers, Molecular Features, and Gene Expression Studies ........................................................................................... 153 Bernard Czernobilsky, Leonor Leider-Trejo, Daniele Fanale, and Antonio Russo 11 Thyroid Carcinoma: Molecular Signature by Histotype-Specifi c Mutations and Gene Expression Patterns ...................................................................... 165 Umberto Malapelle, Claudio Bellevicine, Lajos Pustzai, and Giancarlo Troncone Index ........................................................................................................................................... 179 Contributors Giuseppe Badalamenti , MD, PhD Section of Medical Oncology , Department of Surgical and Oncological Sciences, University of Palermo , Palermo , Italy Claudio Bellevicine , MD Scienze Biomorfologiche e Funzionali , Universita degli Studi di Napoli Federico II , Naples , Italy Ezequiel Luis Calvo , MD, PhD Centre de Recherche du CHUL (CHUQ) , Quebec , PQ , Canada Lidia Corsini , PhD Section of Medical Oncology, Department of Surgical and Oncological Sciences , University of Palermo , Palermo , Italy Bernard Czernobilsky , MD Patho-Lab Diagnostics , Ness Ziona , Israel Jean Charles Dagorn , PhD INSERM U624 , Marseille , France Maria Debiec-Rychter , MD, PhD Department of Human Genetics , Catholic University of Leuven , Leuven , Belgium Nelson Dusetti , PhD INSERM U624 , Marseille , France Mario Falchetti , PhD Department of Molecular Medicine, Policlinico Umberto I, Sapienza University of Rome , Rome , Italy Daniele Fanale , PhD Section of Medical Oncology, Department of Surgical and Oncological Sciences , University of Palermo , Palermo , Italy Pierre Ferrier , PhD Centre d’Immunologie de Marseille-Luminy, Université Aix-Marseille, France CNRS, UMR6102, Marseille, France Inserm, U631, Marseille, France Anna Maria Frezza , MD Department of Medical Oncology , University Campus Bio-Medico , Rome , Italy Gaorav P. Gupta , MD, PhD Department of Radiation Oncology , Memorial Sloan-Kettering Cancer Center , New York , NY , USA Stefano Iacobelli , MD National Consortium for Research on Cancer (CINBO), University D’Annunzio , Chieti , Italy Juan Iovanna , MD, PhD INSERM U624 , Marseille , France ix x Contributors Jinsong Jia , MD, PhD Centre d’Immunologie de Marseille-Luminy, Université Aix-Marseille , France CNRS, UMR6102, Marseille, France Inserm, U631, Marseille, France Institute of Hematology, People’s Hospital, Beijing University, Beijing, People’s Republic of China Laura La Paglia , PhD Section of Medical Oncology, Department of Surgical and Oncological Sciences , University of Palermo , Palermo , Italy Leonor Leider-Trejo , MD Institute of Pathology, Sourasky Medical Center , Tel Aviv , Israel Alessandro Lugli , MD Institute of Pathology, University of Bern , Bern , Switzerland Umberto Malapelle , MD, BS Scienze Biomorfologiche e Funzionali , Universita degli Studi di Napoli Federico II , Naples , Italy John W. M. Martens , PhD Department of Medical Oncology , Daniel den Hoed Cancer Center, Erasmus Medical Center , Rotterdam , The Netherlands Gabriella Nesi , MD, PhD Department of Critical Care Medicine, Division of Pathological Anatomy, University of Florence , Florence , Italy Laura Ottini , MD, PhD Department of Molecular Medicine , Policlinico Umberto I, Sapienza University of Rome , Rome , Italy Aleksandra Pekowska , PhD Centre d’Immunologie de Marseille-Luminy, Université Aix-Marseille, France CNRS, UMR6102, Marseille, France Inserm, U631, Marseille, France Joanna Przybył , MSc Department of Molecular Biology , Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology , Warsaw , Poland Lajos Pustzai , MD, DPhil Department of Breast Medical Oncology , MD Anderson Cancer Center, University of Texas , Houston , TX , USA Stefania Redana , MD Department of Medical Oncology I , Institute for Cancer Research and Treatment, Fondazione Piemontese per L’Oncologia , Candiolo , Italy Sergio Rizzo , MD, PhD Section of Medical Oncology, Department of Surgical and Oncological Sciences , University of Palermo , Palermo , Italy Delvys Rodriguez-Abreu , MD Department of Medical Oncology , Universitario Insular de Gran Canaria , Las Palmas de
Recommended publications
  • Carcinoid) Tumours Gastroenteropancreatic
    Downloaded from gut.bmjjournals.com on 8 September 2005 Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours J K Ramage, A H G Davies, J Ardill, N Bax, M Caplin, A Grossman, R Hawkins, A M McNicol, N Reed, R Sutton, R Thakker, S Aylwin, D Breen, K Britton, K Buchanan, P Corrie, A Gillams, V Lewington, D McCance, K Meeran, A Watkinson and on behalf of UKNETwork for neuroendocrine tumours Gut 2005;54;1-16 doi:10.1136/gut.2004.053314 Updated information and services can be found at: http://gut.bmjjournals.com/cgi/content/full/54/suppl_4/iv1 These include: References This article cites 201 articles, 41 of which can be accessed free at: http://gut.bmjjournals.com/cgi/content/full/54/suppl_4/iv1#BIBL Rapid responses You can respond to this article at: http://gut.bmjjournals.com/cgi/eletter-submit/54/suppl_4/iv1 Email alerting Receive free email alerts when new articles cite this article - sign up in the box at the service top right corner of the article Topic collections Articles on similar topics can be found in the following collections Stomach and duodenum (510 articles) Pancreas and biliary tract (332 articles) Guidelines (374 articles) Cancer: gastroenterological (1043 articles) Liver, including hepatitis (800 articles) Notes To order reprints of this article go to: http://www.bmjjournals.com/cgi/reprintform To subscribe to Gut go to: http://www.bmjjournals.com/subscriptions/ Downloaded from gut.bmjjournals.com on 8 September 2005 iv1 GUIDELINES Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours J K Ramage*, A H G Davies*, J ArdillÀ, N BaxÀ, M CaplinÀ, A GrossmanÀ, R HawkinsÀ, A M McNicolÀ, N ReedÀ, R Sutton`, R ThakkerÀ, S Aylwin`, D Breen`, K Britton`, K Buchanan`, P Corrie`, A Gillams`, V Lewington`, D McCance`, K Meeran`, A Watkinson`, on behalf of UKNETwork for neuroendocrine tumours ..............................................................................................................................
    [Show full text]
  • Guidelines for the Management of Hereditary Colorectal Cancer
    Guidelines Guidelines for the management of hereditary Gut: first published as 10.1136/gutjnl-2019-319915 on 28 November 2019. Downloaded from colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/ United Kingdom Cancer Genetics Group (UKCGG) Kevin J Monahan ,1,2 Nicola Bradshaw,3 Sunil Dolwani,4 Bianca Desouza,5 Malcolm G Dunlop,6 James E East,7,8 Mohammad Ilyas,9 Asha Kaur,10 Fiona Lalloo,11 Andrew Latchford,12 Matthew D Rutter ,13,14 Ian Tomlinson ,15,16 Huw J W Thomas,1,2 James Hill,11 Hereditary CRC guidelines eDelphi consensus group ► Additional material is ABSTRact having a family history of a first-degree relative published online only. To view Heritable factors account for approximately 35% of (FDR) or second degree relative (SDR) with CRC.2 please visit the journal online (http:// dx. doi. org/ 10. 1136/ colorectal cancer (CRC) risk, and almost 30% of the While highly penetrant syndromes such as Lynch gutjnl- 2019- 319915). population in the UK have a family history of CRC. syndrome (LS), familial adenomatous polyposis (FAP) The quantification of an individual’s lifetime risk of and other polyposis syndromes account for account For numbered affiliations see end of article. gastrointestinal cancer may incorporate clinical and for only 5–10% of all CRC diagnoses, advances molecular data, and depends on accurate phenotypic in genetic diagnosis, improvements in endoscopic Correspondence to assessment and genetic diagnosis. In turn this may surgical control, and medical and lifestyle interven- Dr Kevin J Monahan, Family facilitate targeted risk-reducing interventions, including tions provide opportunities for CRC prevention and Cancer Clinic, St Mark’s endoscopic surveillance, preventative surgery and effective treatment in susceptible individuals.
    [Show full text]
  • Evaluation of Response to Neoadjuvant Chemotherapy for Esophageal Cancer: PET Response Criteria in Solid Tumors Versus Response Evaluation Criteria in Solid Tumors
    Journal of Nuclear Medicine, published on May 11, 2012 as doi:10.2967/jnumed.111.098699 Evaluation of Response to Neoadjuvant Chemotherapy for Esophageal Cancer: PET Response Criteria in Solid Tumors Versus Response Evaluation Criteria in Solid Tumors Masahiro Yanagawa*1, Mitsuaki Tatsumi*1,2, Hiroshi Miyata3, Eiichi Morii4, Noriyuki Tomiyama1, Tadashi Watabe2, Kayako Isohashi2, Hiroki Kato2, Eku Shimosegawa2, Makoto Yamasaki3, Masaki Mori3, Yuichiro Doki3, and Jun Hatazawa2 1Department of Radiology, Osaka University Graduate School of Medicine, Suita-city, Osaka, Japan; 2Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Suita-city, Osaka, Japan; 3Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita-city, Osaka, Japan; and 4Department of Pathology, Osaka University Graduate School of Medicine, Suita-city, Osaka, Japan onstrate the correlation between therapeutic responses and Recently, PET response criteria in solid tumors (PERCIST) have prognosis in patients with esophageal cancer receiving neoadju- been proposed as a new standardized method to assess vant chemotherapy. However, PERCIST was found to be the chemotherapeutic response metabolically and quantitatively. strongest independent predictor of outcomes. Given the signifi- The aim of this study was to evaluate therapeutic response to cance of noninvasive radiologic imaging in formulating clinical neoadjuvant chemotherapy for locally advanced esophageal treatment strategies, PERCIST might be considered more suit- cancer, comparing PERCIST with the currently widely used able for evaluation of chemotherapeutic response to esophageal response evaluation criteria in solid tumors (RECIST). Methods: cancer than RECIST. Fifty-one patients with locally advanced esophageal cancer who Key Words: RECIST; PERCIST; 18F-FDG PET; esophageal cancer; received neoadjuvant chemotherapy (5-fluorouracil, adriamycin, response to therapy and cisplatin), followed by surgery were studied.
    [Show full text]
  • The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Inherited Polyposis Syndromes Daniel Herzig, M.D
    CLINICAL PRACTICE GUIDELINES The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Inherited Polyposis Syndromes Daniel Herzig, M.D. • Karin Hardimann, M.D. • Martin Weiser, M.D. • Nancy Yu, M.D. Ian Paquette, M.D. • Daniel L. Feingold, M.D. • Scott R. Steele, M.D. Prepared by the Clinical Practice Guidelines Committee of The American Society of Colon and Rectal Surgeons he American Society of Colon and Rectal Surgeons METHODOLOGY (ASCRS) is dedicated to ensuring high-quality pa- tient care by advancing the science, prevention, and These guidelines are built on the last set of the ASCRS T Practice Parameters for the Identification and Testing of management of disorders and diseases of the colon, rectum, Patients at Risk for Dominantly Inherited Colorectal Can- and anus. The Clinical Practice Guidelines Committee is 1 composed of society members who are chosen because they cer published in 2003. An organized search of MEDLINE have demonstrated expertise in the specialty of colon and (1946 to December week 1, 2016) was performed from rectal surgery. This committee was created to lead interna- 1946 through week 4 of September 2016 (Fig. 1). Subject tional efforts in defining quality care for conditions related headings for “adenomatous polyposis coli” (4203 results) to the colon, rectum, and anus, in addition to the devel- and “intestinal polyposis” (445 results) were included, us- opment of Clinical Practice Guidelines based on the best ing focused search. The results were combined (4629 re- available evidence. These guidelines are inclusive and not sults) and limited to English language (3981 results), then prescriptive.
    [Show full text]
  • Rare Pancreatic Tumors
    Published online: 2020-04-29 THIEME 64 ReviewRare Pancreatic Article Tumors Choudhari et al. Rare Pancreatic Tumors Amitkumar Choudhari1,2 Pooja Kembhavi1,2 Mukta Ramadwar3,4 Aparna Katdare1,2 Vasundhara Smriti1,2 Akshay D. Baheti1,2 1Department of Radiodiagnosis, Tata Memorial Hospital, Mumbai, Address for correspondence Akshay D. Baheti, MD, Department of Maharashtra, India Radiodiagnosis, Tata Memorial Hospital, Ernest , Borges Marg Parel 2Department of Radiodiagnosis, Homi Bhabha National University, Mumbai 400012, India (e-mail: [email protected]). Mumbai, Maharashtra, India 3Department of Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India 4Department of Pathology, Homi Bhabha National University, Mumbai, Maharashtra, India J Gastrointestinal Abdominal Radiol ISGAR 2020;3:64–74 Abstract Pancreatic ductal adenocarcinoma, neuroendocrine tumor, and cystic pancreatic neo- plasms are the common pancreatic tumors most radiologists are familiar with. In this Keywords article we review the clinical presentation, pathophysiology, and radiology of rare pan- ► pancreatic cancer creatic neoplasms. While the imaging features are usually nonspecific and diagnosis is ► uncommon based on pathology, the radiology along with patient demographics, history, and lab- ► pancreatoblastoma oratory parameters can often help indicate the diagnosis of an uncommon pancreatic ► acinar cell neoplasm and guide appropriate management in these cases. ► lymphoma Introduction hyperlipasemia may rarely lead to extraabdominal manifes- tations like ectopic subcutaneous fat necrosis and polyarthri- Pancreatic tumors of various histological subtypes can be tis (lipase hypersecretion syndrome).4 encountered in clinical practice, most common being pan- These tumors are hypoenhancing compared with the pan- creatic ductal adenocarcinoma (PDAC), which constitutes creas and are frequently associated with cystic or necrotic 85% of all pancreatic neoplasms.1 Histologically pancreat- areas as well as calcifications5,6 (►Fig.
    [Show full text]
  • Solid Tumour Section Mini Review
    Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL AT INIST-CNRS Solid Tumour Section Mini Review Lung: Pleuropulmonary blastoma Y Albert Yeh, Morris C Edelman North Shore University Hospital, Long Island Jewish Medical Center, Hofstra University School of Medicine, New York, USA (YAY, MCE) Published in Atlas Database: July 2010 Online updated version : http://AtlasGeneticsOncology.org/Tumors/PleuropulmblastomID6040.html DOI: 10.4267/2042/45006 This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2011 Atlas of Genetics and Cytogenetics in Oncology and Haematology arising in mesenchymal cystic hamartoma, pulmonary Identity blastoma associated with cystic lung disease of Note childhood. Pleuropulmonary blastoma is a rare aggressive malignant tumor of infancy and early childhood. The Clinics and pathology tumor arises in the lung and pleura and is regarded as a pulmonary dysontogenetic or embryonic neoplasm. It is Epidemiology the pulmonary analog of other tumors of childhood There are over 120 cases registered with The including Wilms' tumor, neuroblastoma, Pleuropulmonary Blastoma Registry hepatoblastoma, pancreatoblastoma, and (www.ppbregistry.org). The tumor affects mainly in retinoblastoma. children with age ranges from 1 month to 12 years. Synonyms include embryonal rhabomyosarcoma Most cases are diagnosed before 4 years of age. It can arising in congenital bronchogenic cyst, be found prenatally or present in older children and rhabdomyosarcoma arising in congenital cystic young adults. Males and females are equally affected. adenomatoid malformation, pulmonary sarcoma (A) Type I pleuropulmonary blastoma consists of multiloculated cyst filled with scanty clear serous fluid. (B) The cysts are lined by cuboidal epithelium resting on loose mesenchymal tissue.
    [Show full text]
  • Review of Intra-Arterial Therapies for Colorectal Cancer Liver Metastasis
    cancers Review Review of Intra-Arterial Therapies for Colorectal Cancer Liver Metastasis Justin Kwan * and Uei Pua Department of Vascular and Interventional Radiology, Tan Tock Seng Hospital, Singapore 388403, Singapore; [email protected] * Correspondence: [email protected] Simple Summary: Colorectal cancer liver metastasis occurs in more than 50% of patients with colorectal cancer and is thought to be the most common cause of death from this cancer. The mainstay of treatment for inoperable liver metastasis has been combination systemic chemotherapy with or without the addition of biological targeted therapy with a goal for disease downstaging, for potential curative resection, or more frequently, for disease control. For patients with dominant liver metastatic disease or limited extrahepatic disease, liver-directed intra-arterial therapies including hepatic arterial chemotherapy infusion, chemoembolization and radioembolization are alternative treatment strategies that have shown promising results, most commonly in the salvage setting in patients with chemo-refractory disease. In recent years, their role in the first-line setting in conjunction with concurrent systemic chemotherapy has also been explored. This review aims to provide an update on the current evidence regarding liver-directed intra-arterial treatment strategies and to discuss potential trends for the future. Abstract: The liver is frequently the most common site of metastasis in patients with colorectal cancer, occurring in more than 50% of patients. While surgical resection remains the only potential Citation: Kwan, J.; Pua, U. Review of curative option, it is only eligible in 15–20% of patients at presentation. In the past two decades, Intra-Arterial Therapies for Colorectal major advances in modern chemotherapy and personalized biological agents have improved overall Cancer Liver Metastasis.
    [Show full text]
  • Familial Adenomatous Polyposis Polymnia Galiatsatos, M.D., F.R.C.P.(C),1 and William D
    American Journal of Gastroenterology ISSN 0002-9270 C 2006 by Am. Coll. of Gastroenterology doi: 10.1111/j.1572-0241.2006.00375.x Published by Blackwell Publishing CME Familial Adenomatous Polyposis Polymnia Galiatsatos, M.D., F.R.C.P.(C),1 and William D. Foulkes, M.B., Ph.D.2 1Division of Gastroenterology, Department of Medicine, The Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montreal, Quebec, Canada, and 2Program in Cancer Genetics, Departments of Oncology and Human Genetics, McGill University, Montreal, Quebec, Canada Familial adenomatous polyposis (FAP) is an autosomal-dominant colorectal cancer syndrome, caused by a germline mutation in the adenomatous polyposis coli (APC) gene, on chromosome 5q21. It is characterized by hundreds of adenomatous colorectal polyps, with an almost inevitable progression to colorectal cancer at an average age of 35 to 40 yr. Associated features include upper gastrointestinal tract polyps, congenital hypertrophy of the retinal pigment epithelium, desmoid tumors, and other extracolonic malignancies. Gardner syndrome is more of a historical subdivision of FAP, characterized by osteomas, dental anomalies, epidermal cysts, and soft tissue tumors. Other specified variants include Turcot syndrome (associated with central nervous system malignancies) and hereditary desmoid disease. Several genotype–phenotype correlations have been observed. Attenuated FAP is a phenotypically distinct entity, presenting with fewer than 100 adenomas. Multiple colorectal adenomas can also be caused by mutations in the human MutY homologue (MYH) gene, in an autosomal recessive condition referred to as MYH associated polyposis (MAP). Endoscopic screening of FAP probands and relatives is advocated as early as the ages of 10–12 yr, with the objective of reducing the occurrence of colorectal cancer.
    [Show full text]
  • Immunohistochemical Detection of WT1 Protein in a Variety of Cancer Cells
    Modern Pathology (2006) 19, 804–814 & 2006 USCAP, Inc All rights reserved 0893-3952/06 $30.00 www.modernpathology.org Immunohistochemical detection of WT1 protein in a variety of cancer cells Shin-ichi Nakatsuka1, Yusuke Oji2, Tetsuya Horiuchi3, Takayoshi Kanda4, Michio Kitagawa5, Tamotsu Takeuchi6, Kiyoshi Kawano7, Yuko Kuwae8, Akira Yamauchi9, Meinoshin Okumura10, Yayoi Kitamura2, Yoshihiro Oka11, Ichiro Kawase11, Haruo Sugiyama12 and Katsuyuki Aozasa13 1Department of Clinical Laboratory, National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Osaka, Japan; 2Department of Biomedical Informatics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan; 3Department of Surgery, National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Osaka, Japan; 4Department of Gynecology, National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Osaka, Japan; 5Department of Urology, National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Osaka, Japan; 6Department of Pathology, Kochi Medical School, Kohasu, Oko-cho, Nankoku City, Kochi, Japan; 7Department of Pathology, Osaka Rosai Hospital, Sakai, Osaka, Japan; 8Department of Pathology, Osaka Medical Center and Research Institute of Maternal and Child Health, Izumi, Osaka, Japan; 9Department of Cell Regulation, Faculty of Medicine, Kagawa University, Miki-cho, Kida-gun, Kagawa, Japan; 10Department of Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan; 11Department of Molecular Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan; 12Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Suita, Osaka, Japan and 13Department of Pathology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan WT1 was first identified as a tumor suppressor involved in the development of Wilms’ tumor. Recently, oncogenic properties of WT1 have been demonstrated in various hematological malignancies and solid tumors.
    [Show full text]
  • Prognostic Factors Affecting Mortality in Patients with Esophageal Gists
    JBUON 2020; 25(1): 497-507 ISSN: 1107-0625, online ISSN: 2241-6293 • www.jbuon.com Email: [email protected] ORIGINAL ARTICLE Prognostic factors affecting mortality in patients with esophageal GISTs Dimitrios Schizas1, George Bagias2, Prodromos Kanavidis1, Demetrios Moris1, Eleftherios Spartalis3, Christos Damaskos3, Nikolaos Garmpis3, Ioannis Karavokyros1, Evangelos P. Misiakos4, Theodore Liakakos1 11st Department of Surgery, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece; 2Clinic for General, Visceral and Transplant Surgery, Hannover Medical School, Hannover, Germany; 32nd Department of Propedeutic Surgery, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece; 43rd Department of Surgery, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece. Summary Purpose: Esophageal gastrointestinal stromal tumors (54.3%), followed by tumor enucleation (45.7%). The median (GISTs) compose a very rare clinical entity, representing follow-up period was 34 months; tumor recurrence occurred 0.7% of all GISTs. Therefore, the clinicopathological factors in 18 cases (18.9%) and 19 died of disease (19.2%). The over- that affect mortality are currently not adequately examined. all survival rate was 75.8%. We found out that tumor size We reviewed individual cases of esophageal GISTs found in and high mitotic rate (>10 mitosis per hpf) were significant the literature in order to identify the prognostic factors af- prognostic factors for survival. Presence of symptoms, ul- fecting mortality. ceration, and tumor necrosis as well as tumor recurrence were also significant prognostic factors (p<0.01). Methods: MEDLINE, EMBASE, and the Cochrane Library were systematically searched to identify clinical studies and Conclusions: Esophageal GISTs’ tumor size and mitotic case reports referring to esophageal GISTs.
    [Show full text]
  • Pancreatic Cancer and Liver Cancer Are the Deadliest Cancers; and Still No Effective Chemotherapy
    International Journal of ISSN 2692-5877 Clinical Studies & Medical Case Reports DOI: 10.46998/IJCMCR.2021.10.000240 Perspective Pancreatic Cancer and Liver Cancer Are the Deadliest Cancers; and Still No Effective Chemotherapy. Why? Leslie C Costello* and Renty B Franklin Department of Oncology and Diagnostic Sciences, University of Maryland School of Dentistry and the University of Maryland Greenebaum Comprehensive Cancer Center, USA *Corresponding author: Adel Ekladious, Department of Oncology and Diagnostic Sciences, University of Maryland School of Dentistry; and the University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Md. 21201, USA. Email: [email protected]. Received: May 28, 2021 Published: June 14, 2021 Abstract In 2020, there were about 60,400 cases and 48,200 due to pancreatic cancer; an estimated death rate of 80%. For liver cancer the values are 42,800 new cases and 30,000 deaths; an estimated death rate of 72%. The 5-year survival rate is 9% for pancreatic cancer and 18% for liver cancer. During the recent period of 30 years, there has been no decrease in the incidence of pancreatic cancer deaths or liver deaths; and instead, there has been an increase death. The reason is the continued absence of an efficacious systemic chemotherapy. That is due to the failure of the identification of the important factors that are implicated in the develop- ment and progression of those cancers. However, information does exist, which is likely to represent a viable and compelling concept of the manifestation of both cancers; and will provide the basis for a potential effective chemotherapy. The status of zinc is the likely important factor that manifests the development and progression pancreatic and liver cancers and clioquinol zinc ionophore is the treatment.
    [Show full text]
  • Mtorc1 and FGFR1 Signaling in Fibrolamellar Hepatocellular
    Modern Pathology (2015) 28, 103–110 & 2015 USCAP, Inc. All rights reserved 0893-3952/15 $32.00 103 mTORC1 and FGFR1 signaling in fibrolamellar hepatocellular carcinoma Kimberly J Riehle1,2,3,4, Matthew M Yeh1,2, Jeannette J Yu1,4, Heidi L Kenerson3, William P Harris1,5, James O Park1,3 and Raymond S Yeung1,2,3 1The Northwest Liver Research Program, University of Washington, Seattle, WA, USA; 2Department of Pathology, University of Washington, Seattle, WA, USA; 3Department of Surgery, University of Washington, Seattle, WA, USA; 4Seattle Children’s Hospital, Seattle, WA, USA and 5Department of Medicine, University of Washington, Seattle, WA, USA Fibrolamellar hepatocellular carcinoma, or fibrolamellar carcinoma, is a rare form of primary liver cancer that afflicts healthy young men and women without underlying liver disease. There are currently no effective treatments for fibrolamellar carcinoma other than resection or transplantation. In this study, we sought evidence of mechanistic target of rapamycin complex 1 (mTORC1) activation in fibrolamellar carcinoma, based on anecdotal reports of tumor response to rapamycin analogs. Using a tissue microarray of 89 primary liver tumors, including a subset of 10 fibrolamellar carcinomas, we assessed the expression of phosphorylated S6 ribosomal protein (P-S6), a downstream target of mTORC1, along with fibroblast growth factor receptor 1 (FGFR1). These results were extended and confirmed using an additional 13 fibrolamellar carcinomas, whose medical records were reviewed. In contrast to weak staining in normal livers, all fibrolamellar carcinomas on the tissue microarray showed strong immunostaining for FGFR1 and P-S6, whereas only 13% of non-fibrolamellar hepatocellular carcinomas had concurrent activation of FGFR1 and mTORC1 signaling (Po0.05).
    [Show full text]